



RECEIVED
OCT 28 2003
TECH. CENTER 1630/2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Anderson Et al
Phyllis

Examiner: Spivack,

Serial No.: 10/079,703

Group Art Unit: 1614

Filed: February, 20 2002

Docket: 1/1282

For: PHARMACEUTICAL COMBINATION OF ANGIOTENSIN II ANTAGONISTS
AND ANGIOTENSIN I CONVERTING ENZYME INHIBITORS

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

AMENDMENT UNDER 37 C.F.R. § 1.111
IN RESPONSE TO JULY 22, 2003, OFFICE ACTION

Sir:

This Amendment is filed in response to the Office Action dated July 22, 2003. In that Office Action, a three month shortened statutory period was set for response, and this Amendment is therefore timely. If it is determined that any fees under 37 C.F.R. §§ 1.16 or 1.17 are due in connection with this Amendment, however, authorization is hereby given to charge such fees to Deposit Account No. 02-2955.

Please amend the application as follows.